Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475839 | 0.94 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29646009 | 0.89 | CRBN (0.59) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL30441024 | 0.87 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23729668 | 0.87 | CRBN (0.75) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29227672 | 0.86 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31463319 | 0.86 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25937533 | 0.85 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29264031 | 0.85 | CRBN (0.60) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22291318 | 0.85 | CRBN (0.64) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29521498 | 0.85 | CRBN (0.64) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885ALDH1A1 2600/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885ALDH1A1 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.